search
Back to results

Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction

Primary Purpose

Ultra-short-term, Iron Deficiency Anemia, Scoliosis Idiopathic

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Placebo
ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid
Sponsored by
Tanta University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Ultra-short-term

Eligibility Criteria

13 Years - 45 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients with idiopathic adolescent scoliosis
  • patients with anemia (haemoglobin concentration (Hb) <12g/dL in women and Hb <13 g/dL in men)
  • patients with isolated iron deficiency (ferritin <100 mcg/L, no anemia)

Exclusion Criteria:

  1. Impairments, diseases (renal &/ hepatic) or language problems which do not allow the patient to fully understand the consequences of study participation
  2. Known allergy against iron - carboxymaltose
  3. Hemoglobin concentration (Hb) <90 g/L in both male and female)

Sites / Locations

  • tarek Abdel LattifRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

control group

ultra-short-term treatment

Arm Description

Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.

Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)

Outcomes

Primary Outcome Measures

percentage of patients not required blood transfusion
percentage of patients not required blood transfusion

Secondary Outcome Measures

the length in I.C.U
the length in I.C.U by days
the incidence of acute kidney injury
number of patients developed acute kidney injury
incidence of infections requiring antibiotic treatment
number of patients developed infections requiring antibiotic treatment
perioperative hemoglobin
perioperative hemoglobin by gm
perioperative platelet
perioperative platelet presented as platelet count per microliter of blood
perioperative leucocyte counts
perioperative leucocyte counts presented as white blood cells per microliter
calculated Red blood cells loss
calculated Red blood cells loss by ml

Full Information

First Posted
April 3, 2020
Last Updated
June 10, 2020
Sponsor
Tanta University
search

1. Study Identification

Unique Protocol Identification Number
NCT04343170
Brief Title
Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction
Official Title
Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Unknown status
Study Start Date
April 4, 2020 (Actual)
Primary Completion Date
March 31, 2021 (Anticipated)
Study Completion Date
April 7, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tanta University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Scoliosis is a condition in which there is curvature of the spine occurring in the lateral plane. It occurs in structural forms, characterized by a fixed curve, and "functional" forms, characterized by a flexible or correctable curve. By anatomic necessity, this lateral deviation is associated with vertebral rotation, such that when this deformity occurs in the thoracic spine, a chest wall deformity, or "rib hump," develops. Often there is a primary structural curve with an adjacent secondary compensatory curve. Most cases of structural scoliosis are idiopathic and have their onset in early adolescence. Females are affected more often than males, and their curvature is more likely to worsen. Lumbar fusion surgery is usually associated with massive blood loss. In clinical practice the surgeon might measure the visible peri-operative bleeding including intra- and post-operative drainage, but ignore blood component penetration into the tissues, residual blood in vertebral canal and loss due to haemolysis, which are also known as hidden blood loss. In patients with adolescent idiopathic scoliosis (AIS), surgical treatment involves a posterior approach with multi-segmental pedicle screw fixation. Although this procedure is generally considered safe with few surgical complications, there are considerable variations in fusion length, surgical time, and the extent of soft-tissue exposure. Consequently, perioperative blood loss can be substantial, and the use of intraoperative and postoperative RBC transfusions are frequently required. Patient blood management (PBM) is an evidence-based, multidisciplinary approach developed over the last 10 years focusing on improving patient outcomes as well as reducing the use of RBC transfusions. PBM includes several preventive measures to manage bleeding risks, reduce iatrogenic blood loss, and modify decision thresholds for the appropriate administration of blood therapy. All patients for elective surgery in whom blood loss is expected to be > 500 ml should have their hemoglobin checked pre-operatively and be investigated if they are found to be anemic. In the general population, anemia is defined as a hemoglobin less than 130 g. in men and less than 120g. in women by the WHO. It was proposed that the cut-off value/trigger be changed to hemoglobin more than 130 g for both men and women. Women with hemoglobin levels between 120 and 129 g. are not considered to be anemic according to the WHO definition, leaving them at a potential disadvantage when undergoing major surgery
Detailed Description
44 Patients will be randomly classified into two equal groups each of 22 patients Group I: Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum) Group II: Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo. Either iron or placebo (0•9% saline) were given intravenously via a black infusion set from behind a screen to assure blinding of the patient by a person not involved in data capturing or data entering. Patient's vital signs will be monitored during and at least 15 min after drug application. Treatment will be given one day before the operation Measurements: Demographic data The number of RBC transfusions during the first 7 days. Perioperative course of Hb, (reticulocyte count, reticulocyte Hb content). The need of fresh frozen plasma units transfused in first 7 days The need of platelets units transfused in first 7 days Platelet count. Total leucocyte counts. International normalized ratio. Serum creatinine. C-reactive protein, Calculated RBC loss (preoperative RBC mass minus RBC mass at postoperative fifth day plus transfused RBC mass) Length of ICU stay. Incidence of acute kidney injury Infections requiring antibiotics

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ultra-short-term, Iron Deficiency Anemia, Scoliosis Idiopathic

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
control group
Arm Type
Placebo Comparator
Arm Description
Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
Arm Title
ultra-short-term treatment
Arm Type
Experimental
Arm Description
Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
Intervention Type
Drug
Intervention Name(s)
ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid
Intervention Description
Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
Primary Outcome Measure Information:
Title
percentage of patients not required blood transfusion
Description
percentage of patients not required blood transfusion
Time Frame
up to 7 days postoperative
Secondary Outcome Measure Information:
Title
the length in I.C.U
Description
the length in I.C.U by days
Time Frame
during ICU stay period up to 7 days postoperative
Title
the incidence of acute kidney injury
Description
number of patients developed acute kidney injury
Time Frame
up to 7 days postoperative
Title
incidence of infections requiring antibiotic treatment
Description
number of patients developed infections requiring antibiotic treatment
Time Frame
up to 7 days postoperative
Title
perioperative hemoglobin
Description
perioperative hemoglobin by gm
Time Frame
up to 7 days postoperative
Title
perioperative platelet
Description
perioperative platelet presented as platelet count per microliter of blood
Time Frame
up to 7 days postoperative
Title
perioperative leucocyte counts
Description
perioperative leucocyte counts presented as white blood cells per microliter
Time Frame
up to 7 days postoperative
Title
calculated Red blood cells loss
Description
calculated Red blood cells loss by ml
Time Frame
up to 7 days postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients with idiopathic adolescent scoliosis patients with anemia (haemoglobin concentration (Hb) <12g/dL in women and Hb <13 g/dL in men) patients with isolated iron deficiency (ferritin <100 mcg/L, no anemia) Exclusion Criteria: Impairments, diseases (renal &/ hepatic) or language problems which do not allow the patient to fully understand the consequences of study participation Known allergy against iron - carboxymaltose Hemoglobin concentration (Hb) <90 g/L in both male and female)
Facility Information:
Facility Name
tarek Abdel Lattif
City
Tanta
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
tarek Abdel Lattif, MD
Phone
01003591332
Email
dr.tarek311@yahoo.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction

We'll reach out to this number within 24 hrs